NAUT
NASDAQNautilus Biotechnology Inc.
Price$2.13-0.06 (-2.73%)
01:30 PM07:00 PM
News · 26 weeks29-57%
2026-04-192026-10-11
Mix1490d
- SEC Filings6(43%)
- Other4(29%)
- Earnings2(14%)
- Analyst2(14%)
Latest news
25 items- PRNautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026SEATTLE, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter 2026 before market open on Tuesday, October 27, 2026. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and it
- ANALYSTRoth Capital initiated coverage on Nautilus Biotechnology with a new price targetRoth Capital initiated coverage of Nautilus Biotechnology with a rating of Buy and set a new price target of $3.50
- SECSEC Form EFFECT filed by Nautilus Biotechnology Inc.EFFECT - Nautilus Biotechnology, Inc. (0001808805) (Filer)
- SECSEC Form 424B5 filed by Nautilus Biotechnology Inc.424B5 - Nautilus Biotechnology, Inc. (0001808805) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.SCHEDULE 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)
- SECNautilus Biotechnology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits8-K - Nautilus Biotechnology, Inc. (0001808805) (Filer)
- SECSEC Form S-3 filed by Nautilus Biotechnology Inc.S-3 - Nautilus Biotechnology, Inc. (0001808805) (Filer)
- ANALYSTLeerink Partners initiated coverage on Nautilus Biotechnology with a new price targetLeerink Partners initiated coverage of Nautilus Biotechnology with a rating of Outperform and set a new price target of $4.00
- PRNature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau ProteoformsKey takeaways: Going beyond measurement of bulk tau to quantify each of the diverse proteoforms of tau is key to developing novel diagnostics and precision medicine for Alzheimer’s disease and related tauopathies.Proteoforms – distinct forms of protein that are defined by ordered, non-random combinations of modifications – control biology and are uniquely quantifiable at scale on the Nautilus Voyager Platform.Iterative Mapping of tau resolved 130 tau proteoform groups at scale with precision, sensitivity, and reproducibility, quantifying proteoforms present at 0.1% of a sample, and delivering a median CV below 5.5%.The same validated approach used for tau is now being applied to α-synuclein
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.SCHEDULE 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.SCHEDULE 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)
- SECSEC Form 10-Q filed by Nautilus Biotechnology Inc.10-Q - Nautilus Biotechnology, Inc. (0001808805) (Filer)
- PRNautilus Biotechnology Reports Second Quarter 2026 Financial ResultsSEATTLE, July 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Business Highlights Recognized first revenue in the second quarter of 2026, including grant revenue from the Michael J. Fox Foundation supporting our alpha-synuclein proteoform assay development, together with revenue from our first Iterative Mapping Early Access Program customer.Grew our commercial organization to three team members, including our previously announced VP of Global Sales, driving engagement with prospective Iterative Mapping
- SECNautilus Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Nautilus Biotechnology, Inc. (0001808805) (Filer)
- PRNautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the second quarter 2026 before market open on Tuesday, July 28, 2026. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and its
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.SCHEDULE 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)
- INSIDERSEC Form 4 filed by Director Posard Matthew L.4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
- INSIDERSEC Form 4 filed by Director Akinsanya Karen4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
- INSIDERSEC Form 4 filed by Director Nazem Farzad4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
- INSIDERSEC Form 4 filed by Director Mcilwain Matthew S4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
- INSIDERSEC Form 4 filed by Director Epperly Melissa B,4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
- SECNautilus Biotechnology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Nautilus Biotechnology, Inc. (0001808805) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.SCHEDULE 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)
- INSIDERLarge owner Ah Equity Partners Bio Ii, L.L.C. sold $11,750,000 worth of shares (5,000,000 units at $2.35) (SEC Form 4)4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
- SECSEC Form DEFA14A filed by Nautilus Biotechnology Inc.DEFA14A - Nautilus Biotechnology, Inc. (0001808805) (Filer)
NAUT FAQ
7 questionsWhat does Nautilus Biotechnology Inc. do?
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the human proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company is headquartered in Seattle, Washington.Where does NAUT stock trade?
Nautilus Biotechnology Inc. (NAUT) is listed on NASDAQ.What sector and industry is NAUT in?
Nautilus Biotechnology Inc. operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.When did Nautilus Biotechnology Inc. go public?
Nautilus Biotechnology Inc. (NAUT) completed its IPO in 2020.What are analysts saying about NAUT?
Nautilus Biotechnology Inc. has had 8 recent analyst actions on file. The most recent action was from Roth Capital: Buy with a $350.00 price target on 2026-09-29.What companies are similar to NAUT?
Notable peers in the same industry include A (Agilent Technologies Inc.), WAT (Waters Corporation), MTD (Mettler-Toledo International Inc.), PKI (PerkinElmer Inc.), RVTY (Revvity Inc.). Compare NAUT side-by-side with any of them on Quantisnow.How can I track NAUT on Quantisnow?
Quantisnow aggregates Nautilus Biotechnology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NAUT to receive live email and push alerts on every new disclosure.